Alpha-1 Antitrypsin Deficiency Treatment Market Research Report Information By Drugs (Alpha-1 Proteinase Inhibitor, Bronchodilators, Steroids), Route of Administration (Oral, Intravenous, Inhalation) and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores) - Forecast to 2032

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DRUGS

6.1. Overview

6.2. Alpha-1 Proteinase Inhibitor

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Bronchodilators

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Steroids

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

7.1. Overview

7.2. Oral

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Intravenous

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Inhalation

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DISTRIBUTION CHANNEL

8.1. Overview

8.2. Hospital Pharmacy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Retail Pharmacy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Online Stores

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1.1. Overview

10.1.2. Competitive Analysis

11. COMPANY PROFILES

11.1. Kamada Pharmaceuticals

11.1.1. Company Overview

11.1.2. Drugs Overview

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. CSL Behring LLC

11.2.1. Company Overview

11.2.2. Drugs Overview

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Grifols, S.A.

11.3.1. Company Overview

11.3.2. Drugs Overview

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Takeda Pharmaceutical Company Limited

11.4.1. Company Overview

11.4.2. Drugs Overview

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. GlaxoSmithKline plc

11.5.1. Company Overview

11.5.2. Drugs Overview

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Boehringer Ingelheim GmbH

11.6.1. Company Overview

11.6.2. Drugs Overview

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. AstraZeneca

11.7.1. Company Overview

11.7.2. Drugs Overview

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Vectura Group plc

11.8.1. Company Overview

11.8.2. Drugs Overview

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Pfizer Inc.

11.9.1. Company Overview

11.9.2. Drugs Overview

11.9.3. Financial Overview

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Mylan Inc.

11.10.1. Company Overview

11.10.2. Drugs Overview

11.10.3. Financial Overview

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. Others

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET ESTIMATES & FORECAST, 2020-2027(USD MILLION)

TABLE 3 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DRUGS, 2020-2027(USD MILLION)

TABLE 4 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027(USD MILLION)

TABLE 5 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

TABLE 6 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY REGION, 2020-2027(USD MILLION)

TABLE 7 NORTH AMERICA: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DRUGS, 2020-2027(USD MILLION)

TABLE 8 NORTH AMERICA: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027(USD MILLION)

TABLE 9 NORTH AMERICA: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

TABLE 10 US: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DRUGS, 2020-2027(USD MILLION)

TABLE 11 US: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027(USD MILLION)

TABLE 12 US: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

TABLE 13 CANADA: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DRUGS, 2020-2027(USD MILLION)

TABLE 14 CANADA: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027(USD MILLION)

TABLE 15 CANADA: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

TABLE 16 LATIN AMERICA: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DRUGS, 2020-2027(USD MILLION)

TABLE 17 LATIN AMERICA: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027(USD MILLION)

TABLE 18 LATIN AMERICA: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

TABLE 19 EUROPE: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DRUGS, 2020-2027(USD MILLION)

TABLE 20 EUROPE: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027(USD MILLION)

TABLE 21 EUROPE: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

TABLE 22 WESTERN EUROPE: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DRUGS, 2020-2027(USD MILLION)

TABLE 23 WESTERN EUROPE: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027(USD MILLION)

TABLE 24 WESTERN EUROPE: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

TABLE 25 EASTERN EUROPE: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DRUGS, 2020-2027(USD MILLION)

TABLE 26 EASTERN EUROPE: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027(USD MILLION)

TABLE 27 EASTERN EUROPE: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

TABLE 28 ASIA-PACIFIC: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DRUGS, 2020-2027(USD MILLION)

TABLE 29 ASIA-PACIFIC: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027(USD MILLION)

TABLE 30 ASIA-PACIFIC: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DRUGS, 2020-2027(USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027(USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET

FIGURE 4 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY DRUGS, 2020 (%)

FIGURE 5 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2020 (%)

FIGURE 6 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY DISTRIBUTION CHANNEL, 2020 (%)

FIGURE 7 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE BY REGION, 2020 (%)

FIGURE 8 NORTH AMERICA: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 9 EUROPE: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 WESTERN EUROPE: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 ASIA-PACIFIC: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 MIDDLE EAST & AFRICA: ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 14 KAMADA PHARMACEUTICALS.: KEY FINANCIALS

FIGURE 15 KAMADA PHARMACEUTICALS: SEGMENTAL REVENUE

FIGURE 16 KAMADA PHARMACEUTICALS: REGIONAL REVENUE

FIGURE 17 CSL BEHRING LLC: KEY FINANCIALS

FIGURE 18 CSL BEHRING LLC: SEGMENTAL REVENUE

FIGURE 19 CSL BEHRING LLC: REGIONAL REVENUE

FIGURE 20 GRIFOLS, S.A.: KEY FINANCIALS

FIGURE 21 GRIFOLS, S.A.: SEGMENTAL REVENUE

FIGURE 22 GRIFOLS, S.A.: REGIONAL REVENUE

FIGURE 23 TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY FINANCIALS

FIGURE 24 TAKEDA PHARMACEUTICAL COMPANY LIMITED: SEGMENTAL REVENUE

FIGURE 25 TAKEDA PHARMACEUTICAL COMPANY LIMITED: REGIONAL REVENUE

FIGURE 26 GLAXOSMITHKLINE PLC: KEY FINANCIALS

FIGURE 27 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

FIGURE 28 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

FIGURE 29 BOEHRINGER INGELHEIM GMBH: KEY FINANCIALS

FIGURE 30 BOEHRINGER INGELHEIM GMBH: SEGMENTAL REVENUE

FIGURE 31 BOEHRINGER INGELHEIM GMBH: REGIONAL REVENUE

FIGURE 32 ASTRAZENECA: KEY FINANCIALS

FIGURE 33 ASTRAZENECA: SEGMENTAL REVENUE

FIGURE 34 ASTRAZENECA: REGIONAL REVENUE

FIGURE 35 VECTURA GROUP PLC: KEY FINANCIALS

FIGURE 36 VECTURA GROUP PLC: SEGMENTAL REVENUE

FIGURE 37 VECTURA GROUP PLC: REGIONAL REVENUE

FIGURE 38 PFIZER INC.: KEY FINANCIALS

FIGURE 39 PFIZER INC.: SEGMENTAL REVENUE

FIGURE 40 PFIZER INC.: REGIONAL REVENUE

FIGURE 41 MYLAN INC.: KEY FINANCIALS

FIGURE 42 MYLAN INC.: SEGMENTAL REVENUE

FIGURE 43 MYLAN INC.: REGIONAL REVENUE